Author Archives: zymecom

← Older posts

Mogrify wins Seed Stage Finance Raise of the Year at 2019 European Lifestars Awards

Posted on by zymecom

Cambridge, UK, 20th November 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, is pleased to announce that it has been recognized as the winner of the Seed Stage Finance Raise of the Year … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system

Posted on by zymecom

COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD Headstart is a non-invasive self-test that detects lung biomarkers in the urine Observational, multi-centre validation trial carried out in collaboration with a consortium … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Optibrium collaborates with Enamine and BioSolveIT to add REAL Space Search Tool to StarDrop

Posted on by zymecom

New extension enables researchers to explore the REAL Space of 11 billion readily accessible compounds directly from StarDrop CAMBRIDGE, UK, KIEV, UKRAINE and SANKT AUGUSTIN, GERMANY, 19 November, 2019 – Optibrium™, BioSolveIT™ and Enamine™, leading providers of software and services … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

LUNAC Therapeutics spun out to develop next generation anticoagulants, and announces Series A funding round

Posted on by zymecom

Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds  Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Turbine secures €3 million EUR seed fund to expand the potential of simulation-first drug discovery

Posted on by zymecom

Simulation-first approach provides deeper understanding of cancer cells, and supports rational decision-making to unlock new treatments Company’s first institutional funding will be used to expand workflow across all phases of drug discovery  London, UK & Budapest, Hungary, 13 November 2019: … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

LG Chem Life Sciences Expands Partnership with Avacta Group plc

Posted on by zymecom

LG Chem selects second and third drug targets following rapid progress in first programme Cambridge, UK, 13 November 2019: Avacta Group plc (AIM:AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to provide an update on the Affimer therapeutics … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

TTP plc Desktop Biology enables development and manufacture of DnaNudge technology

Posted on by zymecom

Novel multiplex technology developed to help consumers make healthier choices based on their genetic profile TTP involved with all aspects of product development, from initial concept to prototype testing and manufacture Culmination of technology and product development partnership spanning just … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Mesa Labs Acquires Gyros Protein Technologies

Posted on by zymecom

Lakewood, CO, USA, 11 November 2019: Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Owlstone Medical Enters Collaboration to Advance Early Disease Detection Using Non-Invasive Breath Biopsy

Posted on by zymecom

Thermo Fisher Scientific Orbitrap GC-MS technology to be integrated into Breath Biopsy to support identification of novel biomarkers for early disease detection Cambridge, UK, November 07 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Owlstone Medical Enters Collaboration to Advance Early Disease Detection Using Non-Invasive Breath Biopsy

Femtogenix presents novel data on antibody drug conjugates containing reduced potency payloads in solid tumour models

Posted on by zymecom

Data demonstrate potent efficacy and favourable toxicity profile of a reduced potency, sequence-selective DNA mono-alkylator Represents a promising new approach in ADC development, specifically for the treatment of solid tumour malignancies Data presented at AACR-NCI-EORTC International Conference on Molecular Targets … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Femtogenix presents novel data on antibody drug conjugates containing reduced potency payloads in solid tumour models ← Older posts
  • People

    An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.

  • Keep in touch

    +44(0) 1223 968 920

    info@zymecommunications.com


     

  • Upcoming Events

    Zyme Communications will be providing support for its clients attending the following events:

    ASCB Annual Meeting

    When: Sat December 7 09:00 - Wed December 11 18:00
    Where: Washington, USA

    LSX World Congress

    When: Tue February 4 2020 09:00 - Wed February 5 18:00
    Where: London, UK